21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA, CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections. In silico...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Debiopharm, Solid Biosciences deal

The companies partnered to conduct preclinical studies of Debiopharm’s alisporivir ( Debio 025) to treat Duchenne muscular dystrophy (DMD). Debiopharm will fund the studies of the oligopeptide cyclophilin inhibitor. The partners declined to disclose...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV Cyclophilin Cell culture studies suggest nonimmunosuppressive cyclosporine-based cyclophilin inhibitors could help treat HCV infections with...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Alisporivir: Phase I started

Novartis began an open-label Phase I trial evaluating alisporivir in combination with EDP-239 in about 42 healthy volunteers. EDP-239, an HCV NS5A protein inhibitor, is in Phase I testing to treat HCV infection....
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

EDP-239: Phase I

Novartis began an open-label Phase I trial evaluating alisporivir in combination with EDP-239 in about 42 healthy volunteers. EDP-239 is in Phase I testing to treat HCV infection. Alisporivir, an oligopeptide cyclophilin inhibitor, is...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

DEB025: Development resumed

Novartis disclosed in its 3Q13 earnings that during the quarter it resumed clinical development of DEB025, which is in Phase II testing to treat HCV infection. In 2012, FDA placed a clinical hold on DEB025...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
07:00 , Apr 30, 2012 |  BioCentury  |  Strategy

With or without you

Bristol-Myers Squibb Co. is preparing for Plan B in the event that Gilead Sciences Inc. decides against moving the their NS5A-nuc combination into Phase III testing for HCV. A split could delay by at least...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

Alisporivir: Development hold

Novartis said FDA placed a full clinical hold on HCV compound alisporivir following the death of 1 patient in a double-blind, placebo-controlled, international Phase III trial evaluating the compound plus standard of care (SOC; peginterferon...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Clinical News

Alisporivir: Phase II data

The double-blind, international Phase II FUNDAMENTAL (A2210) trial in 461 patients with chronic HCV genotype 1 infection who relapsed or were non-responders to standard of care (SOC; peginterferon alfa-2a and ribavirin) showed that alisporivir plus...